Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,267 across all filing types
Latest filing 2019-08-01 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a newspaper advertisement about a Notice of Board Meeting. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure requirements for listed companies. The content is about announcing the scheduling of a Board Meeting, not the meeting materials themselves or any financial report. The document length is short (1802 characters), and it is an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-08-01 English
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on August 1, 2019 ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for August 7, 2019, to consider and approve the unaudited financial results for the quarter ended June 30, 2019. It is a newspaper advertisement pursuant to SEBI regulations informing about the Board Meeting date and agenda. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement related to a Board Meeting and financial results approval, not the results or report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance notice rather than a full Interim Report or Earnings Release.
2019-08-01 English
AstraZeneca Pharma India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 07, 2019, inter alia, to:1. consider and approve the ....
Capital/Financing Update Classification · 90% confidence The document is a letter from AstraZeneca Pharma India Limited addressed to stock exchanges, informing about an upcoming Board of Directors meeting scheduled for August 7, 2019. The agenda includes consideration and approval of unaudited financial results for the quarter ended June 30, 2019, and declaration of an interim dividend. The document also mentions the closure of the trading window for insiders. The document is short (2070 characters) and serves as a notification of a future board meeting and financial results approval, not the actual financial report or results themselves. It does not contain financial data or detailed analysis. Therefore, it is an announcement related to capital/financing activities and interim dividend declaration, but primarily it is a notice of a board meeting to approve financial results and dividend. Given the content and context, the best fitting category is Capital/Financing Update (CAP).
2019-07-29 English
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2019 ,inter alia, to consider and approve This is to inform ....
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Limited addressed to stock exchanges notifying about an upcoming Board of Directors meeting scheduled for August 7, 2019. The agenda includes consideration and approval of unaudited financial results for the quarter ended June 30, 2019, and declaration of an interim dividend. The document also mentions the closure of the trading window for insiders. The document is short (2070 characters) and serves as an announcement of a future board meeting and financial results approval, not the financial results report itself. It does not contain actual financial data or detailed financial statements. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release. The document is not a report publication announcement because it does not mention the report being published or attached, but rather the meeting to approve results.
2019-07-29 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a letter from AstraZeneca Pharma India Limited addressed to stock exchanges notifying about an upcoming Board of Directors meeting scheduled for August 7, 2019. The agenda includes consideration and approval of unaudited financial results for the quarter ended June 30, 2019, and declaration of an interim dividend. The document also mentions the closure of the trading window for insiders. The document is short (2070 characters) and serves as an announcement of a future board meeting and financial results approval, not the financial results report itself. Therefore, it is not an Interim/Quarterly Report (IR) or Earnings Release (ER). It is an announcement related to corporate governance and board activities, but specifically about a meeting notice. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification to exchanges about board meetings and financial results approval schedules. It is not a full report, nor a proxy or AGM material, nor a dividend notice (since dividend declaration is only to be considered, not declared yet).
2019-07-29 English
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting with investors/analysts is scheduled to be ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about scheduled meetings with analysts and institutional investors. It references Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, which mandates disclosure of such interactions. The content is a notification of upcoming investor meetings, not a financial report, earnings release, or detailed presentation. The document length is short (1939 characters), and it serves as an announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2019-07-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.